ROSABULIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H16N4O2S
Molecular Weight	400.453
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NSC(NC(=O)C(=O)C2=C3C=CC=CN3C(CC4=CC=C(C=C4)C#N)=C2)=C1

InChI

InChIKey=IZZYUABKZYIINT-UHFFFAOYSA-N

InChI=1S/C22H16N4O2S/c1-14-10-20(29-25-14)24-22(28)21(27)18-12-17(26-9-3-2-4-19(18)26)11-15-5-7-16(13-23)8-6-15/h2-10,12H,11H2,1H3,(H,24,28)

HIDE SMILES / InChI

Description
Sources: https://pubchem.ncbi.nlm.nih.gov/compound/Rosabulin | https://clinicaltrials.gov/ct2/show/NCT00276913 | https://clinicaltrials.gov/ct2/show/NCT00088101

Rosabulin (STA 5312) is an antineoplastic compound (inhibiting or halting neoplasm development). This compound was developed for the treatment of drug resistant tumors. By acting as a tubulin inhibitor, rosabulin hinders the microtubule assembly necessary to shape endothelial (vascular) cells, and blocks their cell division. As a result, blood flow to the tumor is reduced and tumor cell proliferation is decreased. Phase I clinical trials in patients with advanced or metastatic tumors, leukemia, lymphoma and hematological malignancies have evaluated the safety and toxicity of rosabulin. Development of rosabulin has been discontinued in 2008.

Originator

Approval Year

Name

Type

Language

ROSABULIN

Official Name

English

ROSABULIN [USAN]

Common Name

English

STA-5312

Code

English

rosabulin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C25974